The overall incidence of head and neck cancer has declined in the United States over the past 30 years due to reduction in tobacco use. Over that same period, however, the worldwide incidence of oropharyngeal cancer has escalated significantly—an epidemic rise that is largely attributed to certain genotypes of the human papillomavirus (HPV). AJN’s editor-in-chief Shawn Kennedy speaks with lead author Janet McKiernan about her article, which provides an overview of head and neck cancer—its incidence, risk factors, treatment, and posttreatment sequelae—with a focus on HPV-related oropharyngeal cancer.